Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3105 SEK | -2.82% | -2.82% | -23.80% |
Mar. 26 | Transcript : Vivesto AB - Special Call | |
Mar. 07 | Vivesto AB Doses First Patient in its Clinical Paccal Vet Trial | CI |
Sales 2021 | 28.87M 2.7M | Sales 2022 | 3.04M 285K | Capitalization | 234M 21.87M |
---|---|---|---|---|---|
Net income 2021 | -133M -12.45M | Net income 2022 | -357M -33.43M | EV / Sales 2021 | 37.7 x |
Net cash position 2021 | 86.84M 8.13M | Net cash position 2022 | 134M 12.58M | EV / Sales 2022 | 32.6 x |
P/E ratio 2021 |
-8.86
x | P/E ratio 2022 |
-0.6
x | Employees | 14 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 61.42% |
Latest transcript on Vivesto AB
1 day | -2.82% | ||
1 week | -2.82% | ||
Current month | +10.70% | ||
1 month | +3.67% | ||
3 months | -36.83% | ||
6 months | +38.93% | ||
Current year | -23.80% |
Managers | Title | Age | Since |
---|---|---|---|
Erik Kinnman
CEO | Chief Executive Officer | 66 | 23-01-22 |
Robert Maiorana
DFI | Director of Finance/CFO | 64 | 20-11-30 |
Heidi Ramstad
CTO | Chief Tech/Sci/R&D Officer | 55 | 21-02-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 44 | 19-03-18 | |
Hege Hellstrom
BRD | Director/Board Member | 59 | 19-09-25 |
Pål Ryfors
BRD | Director/Board Member | 41 | 22-05-24 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 0.3105 | -2.82% | 269,270 |
24-03-27 | 0.3195 | -2.29% | 678,342 |
24-03-26 | 0.327 | +3.32% | 595,626 |
24-03-25 | 0.3165 | -0.78% | 1,552,151 |
24-03-22 | 0.319 | -0.16% | 557,901 |
Delayed Quote Nasdaq Stockholm, March 28, 2024 at 07:44 am EDT
More quotesAnnual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-23.80% | 15.64M | |
+33.46% | 701B | |
+26.24% | 570B | |
+0.93% | 381B | |
+21.03% | 334B | |
+17.51% | 322B | |
+2.95% | 212B | |
+0.74% | 209B | |
-6.05% | 205B | |
-3.61% | 157B |